Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @CRISPRTX
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CRISPRTX
-
Congratulations to our co-founder Emmanuelle Charpentier and
@UCBerkeley professor Jennifer Doudna on winning the 2020 Wolf Prize in Medicine for their pioneering work in CRISPR-Cas9 gene-editing technology! Learn more here:https://bit.ly/30p5rNJHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
And
#ASH2019 is a wrap! Team$CRSP had a great time connecting with colleagues, peers, and industry leaders. Thanks@ASH_hematology for a great conference and thanks to everyone who came by our booth!pic.twitter.com/UWgp18H41E
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CRSP and@VertexPharma announce early positive safety and efficacy data from the first two patients treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 for severe hemoglobinopathies. Learn more here:https://bit.ly/2Kx4jRuHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Several proud members of team
$CRSP highlighting data at#SITC19! We’re moving at a rapid pace, and every day presents new excitements and challenges. Want to be a part of our groundbreaking team? Learn more here: http://www.crisprtx.com/careers pic.twitter.com/QBcjhiBbaT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#SITC19? Stop by our poster (#P187). We’ll be highlighting data related to single-cell RNA sequencing and functional assessment of healthy donor and cancer patient-derived T and CAR-T cells.pic.twitter.com/X5ZUoGsmFX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We were thrilled to host our 2019 Volunteer Day this week in partnership with
@LS_Cares and@c2cboston, making over 80 blankets, 40 Happy Hope Bags and sorting donated clothing, impacting over 1,000 children in the Greater Boston area. Thanks to all of our employees!pic.twitter.com/opzDFVPhE5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CRSP provides business update and reports Q3 2019 financial results. Learn more in our press release:https://bit.ly/31QjTNVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today
$CRSP and Bayer shared an update on Casebia Therapeutics. Learn more in the press release:https://bit.ly/2J722f4Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We were excited to meet those in the
#SickleCellDisease community last week@SCDAAorg’s Annual National Convention where our Head of R&D Tony Ho spoke about our efforts to advance treatments for SCD#SCDAA47Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CRSP and@KSQ_TX announce license agreement to advance companies’ respective cell therapy programs in oncology. Learn more here:https://bit.ly/2ISvSE6Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#USPTO has issued a new patent to the Charpentier/Doudna teams, covering new compositions and methods. Learn more here:https://prn.to/2mSxaH5Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#USPTO has issued a new patent to the Charpentier/Doudna teams, covering single-molecule guide RNA compositions and other methods. Learn more here:https://prn.to/2kqSMJMHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today,
$CRSP and@ViaCyte presented data on a regenerative medicine program targeted towards type 1 diabetes at#EASD2019 showing successful differentiation of CRISPR-edited human pluripotent stem cells to pancreatic precursor cells. Learn more here:https://bit.ly/2lZEcckHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
$CRSP team had an amazing day at the annual walk for#SickleCellDisease. Thanks to all the supporters who joined us to raise awareness.#SickleCellAwarenessMonthpic.twitter.com/wDSln7iCHz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excited to have been part of the
#SCDTC where our Head of Hemoglobinopathies Programs Krista McKerracher spoke on our approach to treating#SickleCellDisease. Learn more about our work here: https://bit.ly/2m514at#SickleCellAwarenessMonthHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#USPTO has granted a new patent to the Charpentier/Doudna teams related to single-guide RNAs. Learn more here:https://prn.to/2kErM9zHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CRSP provides business update and reports Q2 2019 financial results. Learn more in our press release:https://bit.ly/2K3MDNIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#USPTO has issued two new patents to the Charpentier/Doudna teams that cover methods of targeting and binding, modifying or cleaving a target DNA. Learn more here:https://prn.to/2M7zaG4Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Team
@CRISPRTX spent the afternoon at Fenway Park cheering on the Red Sox to a win!pic.twitter.com/fJyrAZYxw7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#USPTO has issued a new patent to the Charpentier/Doudna teams which involves introducing Cas9 into a cell for genome editing. Learn more here:https://prn.to/2Ya6kuQHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.